29.03.2012 22:35 Uhr, Quelle: Wallstreet online

Shire Reaffirms Support of Patients Requiring Midodrine HCl; Advances FDA Agreed Upon Clinical Trials

PHILADELPHIA, March 29, 2012 /PRNewswire/ FDA´s Complete Response Letter for droxidopa as a possible orthostatic hypotension treatment highlights importance of Shire´s commitment to complete additional trials to verify and describe the …

Weiterlesen bei Wallstreet online